Delving into the Latest Updates on Oglufanide disodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Glufanide disodium, Glutamyltryptophan, L-Glu-L-Trp

+ [9]

Target-

Action

inhibitors, modulators

Mechanism

Angiogenesis inhibitors, Immunomodulators

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [5]

Active Indication-

Inactive Indication

Acquired Immunodeficiency SyndromeBacterial InfectionsColorectal Cancer+ [5]

Originator Organization

ALZA Corp.

Active Organization-

Inactive Organization

Cytran, Inc.

Implicit Bioscience Ltd.

ALZA Corp.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC16H19N3NaO5

InChIKeyUOKXDTZUCQYLHK-JZKFLRDJSA-N

CAS Registry237068-57-4

View All Structures (2)

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill tumor cells. Combining chemotherapy and IM-862 may kill more tumor cells.
PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy and IM-862 in treating patients who have resected stage III ovarian cancer or primary peritoneal cancer.

Start Date01 Jan 2001

Sponsor / Collaborator

Cytran, Inc.

NCT00006037

/ TerminatedPhase 2IIT

Phase II Randomized Placebo-Controlled Double-Blinded Study With 5-FU vs. 5-FU With IM862 With Cross-Over to CPT-11 vs. CPT-11 With IM862

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known if chemotherapy is more effective with or without IM-862 in treating colorectal cancer.
PURPOSE: Randomized phase II trial to study the effectiveness of chemotherapy plus IM-862 in treating patients who have metastatic colorectal cancer.

Start Date01 Nov 1999

Sponsor / Collaborator

University of Southern California

[+1]

100 Clinical Results associated with Oglufanide disodium

Login to view more data

100 Translational Medicine associated with Oglufanide disodium

Login to view more data

100 Patents (Medical) associated with Oglufanide disodium

Login to view more data

249

Literatures (Medical) associated with Oglufanide disodium

01 Feb 2025·Analytica Chimica Acta

Enhanced nano-LC-MS for analyzing dansylated oral cancer tissue metabolome dissolved in solvents with high elution strength

Article

Author: Chang, Kai-Ping ; Chiang, Wei-Fan ; Lin, Yu-Tsun ; Hsieh, Ya-Ju ; Chen, Yi-Ting ; Hung, Cheng-Yu ; Yu, Jau-Song ; Wu, Chih-Ching ; Li, Liang ; Chien, Chih-Yen ; Chien, Kun-Yi

BACKGROUNDTissue metabolomics analysis, alongside genomics and proteomics, offers crucial insights into the regulatory mechanisms of tumorigenesis. To enhance metabolite detection sensitivity, chemical isotope labeling (CIL) techniques, such as dansylation, have been developed to improve metabolite separation and ionization in mass spectrometry (MS). However, the dissolution of hydrophobic derivatized metabolites in solvents with high acetonitrile content limits the use of liquid chromatography (LC) systems with small-volume reversed-phase (RP) columns. In this study, we established a nano-LC-MS system with an online dilution design to address this issue, enabling sensitive analysis of oral cancer tissue metabolomes.RESULTSOur nano-LC system features a flow path design with online sample dilution before an RP trap column and backflushing of the trap column before entering the analytical column. Compared to other nano-LC systems, both with and without online dilution designs, our system demonstrates the superiority of the T-connector-based dilution method. Using only 1/20th of the sample required for popular micro-LC systems, our nano-LC detects a larger number of peak pairs with similar recovery rates for both hydrophilic and hydrophobic metabolites, ensuring unbiased results. Thirty-two matched pairs of oral squamous cell carcinoma (OSCC) tissue samples and adjacent noncancerous tissues (ANTs) underwent high-throughput CIL-metabolome analysis using our nano-LC system. Compared to our previous micro-LC methods, the nano-LC-MS system exhibits enhanced detection sensitivity, significantly reducing sample requirements.SIGNIFICANCEOur findings highlight the efficacy of our platform for metabolomic analysis with limited sample amounts. The nano-LC system's ability to analyze samples dissolved in strong eluents suggests potential applications for handling other hydrophobic compounds using RPLC or other separation methods facing similar solvent incompatibility issues. This approach holds promise for identifying novel metabolite biomarkers for oral cancers, advancing our understanding of tumorigenesis, and enhancing clinical applications.

01 Nov 2024·Biomedical Chromatography

Mass spectrometry‐based metabolomics reveals metabolism of molnupiravir may lead to metabolic disorders and hepatotoxicity

Article

Author: Li, Bin ; Liu, Hongning ; Yan, Dongmei ; Cheng, Yan ; Chen, Jiahui ; Li, Fei ; Zhao, Qi ; Chen, Liqiong

AbstractMolnupiravir (MO) is a pyrimidine nucleoside anti‐SARS‐CoV‐2 drug. MO treatment could cause mild liver injury. However, the underlying mechanism of MO‐induced liver injury and the metabolic pathway of MO in vivo are unclear. In this study, metabolomics analysis and molecular biology methods were used to explore these issues. Through metabolomics analysis, it was found that the homeostasis of pyrimidine, purine, lysophosphatidylcholine (LPC), and amino acids in mice was destroyed after MO treatment. A total of 80 changed metabolites were detected. Among these changed metabolites, 4‐ethylphenyl sulfate, dihydrouracil, and LPC 20:0 was related to the elevation of alkaline phosphatase (ALP), interleukin‐6 (IL6), and nuclear factor kappa‐B (NF‐κB). The levels of 4‐ethylphenyl sulfate, dihydrouracil, and LPC 20:0 in plasma were positively correlated with their levels in the liver, suggesting that these metabolites were associated with MO‐induced liver injury. MO treatment could increase NHC and cytidine levels, activate cytidine deaminase (CDA), and increase LPC levels. CDA and LPC could increase the mRNA expression level of toll‐like receptor (TLR). The current study indicated that the elevation of hepatic TLR may be an important reason for MO leading to the liver injury.

01 Nov 2024·Food Research International

Identification of salty peptides from enzymolysis extract of oyster by peptidomics and virtual screening

Article

Author: Wang, Haiyan ; Ye, Xingqian ; Lu, Wenjing ; Cheng, Huan ; Liu, Donghong ; Xiao, Chaogeng ; Lai, Zeping ; Huang, Liquan ; Chen, Di ; Zhang, Cen

Salty peptide as an important sodium substitute, which could reduce the risk of cardiovascular disease caused by excessive sodium intake. In this study, novel salty peptides were prepared and identified from enzymolysis extract of oysters by peptitomic identification, virtual screening and solid phase synthesis. Additionally, molecular simulation was used to study the taste mechanism of salty peptides. 316 peptides were identified in the enzymatic hydrolysates of oysters. 6 peptides, selected through virtual screening, were synthesized using solid-phase synthesis, and EK, LFE, LEY and DR were confirmed to possess a pleasing salty taste through electronic tongue evaluation. Molecular docking results indicated that these 4 peptides could enter the binding pocket within the transmembrane channel-like 4 (TMC4) cavity, wherein salt bridges, hydrogen bonds and attractive charges were the main binding forces. This study provides a rapid screening method for salty peptides in sea food products but possibly applied for other sources.

100 Deals associated with Oglufanide disodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05235	-	-	DB05779

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	Phase 3	Australia	Cytran, Inc.	31 Aug 2001
Acquired Immunodeficiency Syndrome	Phase 3	Canada	Cytran, Inc.	31 Aug 2001
Acquired Immunodeficiency Syndrome	Phase 3	Belgium	Cytran, Inc.	31 Aug 2001
Acquired Immunodeficiency Syndrome	Phase 3	United States	Cytran, Inc.	31 Aug 2001
Colorectal Cancer	Phase 3	United States	Implicit Bioscience Ltd.	-
Hepatitis C	Phase 3	Australia	Implicit Bioscience Ltd.	-
Kaposi Sarcoma	Phase 3	-	Implicit Bioscience Ltd.	-
Kaposi Sarcoma	Phase 3	-	ALZA Corp.	-
Kaposi Sarcoma	Phase 3	-	ALZA Corp.	-
Kaposi Sarcoma	Phase 3	-	Implicit Bioscience Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2024	Not Applicable	Gastritis, Atrophic H. pylori	116	Alpha-glutamyl-tryptophan	jzqtaubxug(ymulblbvhh) = decrease of GM edema and hyperemia by endoscopy data, reduction of the number of inflammatory infiltration cells per 1 mm 2 of GM: eosinophilic granulocytes â 3 times, neutrophilic leukocytes â 4 times, macrophages â 1.5 times, lymphocytes â 28.2%, plasmocytes â 29.6% by histological study pbgmenwtlo (ugfndjbrrd ) View more	Positive	13 Oct 2024
ASCO2005	Phase 2	Castration-sensitive prostate cancer	-	IM862	ljjancfebm(weyobxjhth) = dtsfyewyyx awzhuwzqzj (wzuoyykkpl )	Negative	01 Jun 2005
ASCO2005	Phase 2	Castration-sensitive prostate cancer	-	Placebo	ljjancfebm(weyobxjhth) = jkdrhyytln awzhuwzqzj (wzuoyykkpl )	Negative	01 Jun 2005